|
1
|
Clark JC, Dass CR and Choong PF: A review
of clinical and molecular prognostic factors in osteosarcoma. J
Cancer Res Clin Oncol. 134:281–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shao Y, Geng Y, Gu W, Huang J, Pei H and
Jiang J: Prognostic role of tissue and circulating microRNA-200c in
malignant tumors: A systematic review and meta-analysis. Cell
Physiol Biochem. 35:1188–1200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bielack SS, Hecker-Nolting S, Blattmann C
and Kager L: Advances in the management of osteosarcoma. F1000Res.
5:27672016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dalmay T: Mechanism of miRNA-mediated
repression of mRNA translation. Essays Biochem. 54:29–38. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Kouwenhove M, Kedde M and Agami R:
MicroRNA regulation by RNA-binding proteins and its implications
for cancer. Nat Rev Cancer. 11:644–656. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nugent M: microRNA and bone cancer. Adv
Exp Med Biol. 889:201–230. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rehei AL, Zhang L, Fu YX, Mu WB, Yang DS,
Liu Y, Zhou SJ and Younusi A: MicroRNA-214 functions as an oncogene
in human osteosarcoma by targeting TRAF3. Eur Rev Med Pharmacol
Sci. 22:5156–5164. 2018.PubMed/NCBI
|
|
9
|
Xie W, Xiao J, Wang T, Zhang D and Li Z:
MicroRNA-876-5p inhibits cell proliferation, migration and invasion
by targeting c-Met in osteosarcoma. J Cell Mol Med. 23:3293–3301.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang J, Liu L, Sun Y, Xue Y, Qu J, Pan S,
Li H, Qu H, Wang J and Zhang J: miR-615-3p promotes proliferation
and migration and inhibits apoptosis through its potential target
CELF2 in gastric cancer. Biomed Pharmacother. 101:406–413. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen L, Nan A, Zhang N, Jia Y, Li X, Ling
Y, Dai J, Zhang S, Yang Q, Yi Y and Jiang Y: Circular RNA 100146
functions as an oncogene through direct binding to miR-361-3p and
miR-615-5p in non-small cell lung cancer. Mol Cancer. 18:132019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Q, Wu G, Zhang Z, Tang Q, Zheng W,
Chen X, Chen F, Li Q and Che X: Long non-coding RNA HOTTIP promotes
renal cell carcinoma progression through the regulation of the
miR-615/IGF-2 pathway. Int J Oncol. 53:2278–2288. 2018.PubMed/NCBI
|
|
13
|
Yang B, Xie R, Wu SN, Gao CC, Yang XZ and
Zhou JF: MicroRNA-615-5p targets insulin-like growth factor 2 and
exerts tumor-suppressing functions in human esophageal squamous
cell carcinoma. Oncol Rep. 39:255–263. 2018.PubMed/NCBI
|
|
14
|
Zhong JT and Zhou SH: Warburg effect,
hexokinase-II, and radioresistance of laryngeal carcinoma.
Oncotarget. 8:14133–14146. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiao L, Zhang HL, Li DD, Yang KL, Tang J,
Li X, Ji J, Yu Y, Wu RY, Ravichandran S, et al: Regulation of
glycolytic metabolism by autophagy in liver cancer involves
selective autophagic degradation of HK2 (hexokinase 2). Autophagy.
14:671–684. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Z, Huang S, Wang H, Wu J, Chen D,
Peng B and Zhou Q: High expression of hexokinase domain containing
1 is associated with poor prognosis and aggressive phenotype in
hepatocarcinoma. Biochem Biophys Res Commun. 474:673–679. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wei L, Zhou Y, Dai Q, Qiao C, Zhao L, Hui
H, Lu N and Guo QL: Oroxylin A induces dissociation of hexokinase
II from the mitochondria and inhibits glycolysis by SIRT3-mediated
deacetylation of cyclophilin D in breast carcinoma. Cell Death Dis.
4:e6012013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xi F and Ye J: Inhibition of lung
carcinoma A549 cell growth by knockdown of hexokinase 2 in situ and
in vivo. Oncol Res. 23:53–59. 2016. View Article : Google Scholar
|
|
19
|
Mukherjee A, Ma Y, Yuan F, Gong Y, Fang Z,
Mohamed EM, Berrios E, Shao H and Fang X: Lysophosphatidic acid
up-regulates hexokinase II and glycolysis to promote proliferation
of ovarian cancer cells. Neoplasia. 17:723–734. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu J, Wang L, Chen W, Wang Y, Zhen S, Chen
H, Cheng J, Zhou Y, Li X and Zhao L: miR-603 targeted hexokinase-2
to inhibit the malignancy of ovarian cancer cells. Arch Biochem
Biophys. 661:1–9. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang T, Zhu X, Wu H, Jiang K, Zhao G,
Shaukat A, Deng G and Qiu C: Targeting the ROS/PI3K/AKT/HIF-1α/HK2
axis of breast cancer cells: Combined administration of Polydatin
and 2-Deoxy-d-glucose. J Cell Mol Med. 23:3711–3723. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fu JH, Yang S, Nan CJ, Zhou CC, Lu DQ, Li
S and Mu HQ: MiR-182 affects renal cancer cell proliferation,
apoptosis, and invasion by regulating PI3K/AKT/mTOR signaling
pathway. Eur Rev Med Pharmacol Sci. 22:351–357. 2018.PubMed/NCBI
|
|
23
|
Guanen Q, Junjie S, Baolin W, Chaoyang W,
Yajuan Y, Jing L, Junpeng L, Gaili N, Zhongping W and Jun W:
MiR-214 promotes cell meastasis and inhibites apoptosis of
esophageal squamous cell carcinoma via PI3K/AKT/mTOR signaling
pathway. Biomed Pharmacother. 105:350–361. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu RD, Feng F, Yu XS, Liu ZD and Lao LF:
miR-149-5p inhibits cell growth by regulating TWEAK/Fn14/PI3K/AKT
pathway and predicts favorable survival in human osteosarcoma. Int
J Immunopathol Pharmacol. 32:20587384187866562018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Z, Luo G, Yu C, Yu G, Jiang R and
Shi X: MicroRNA-493-5p inhibits proliferation and metastasis of
osteosarcoma cells by targeting Kruppel-like factor 5. J Cell
Physiol. 234:13525–13533. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dong Y, Huo X, Sun R, Liu Z, Huang M and
Yang S: lncRNA Gm15290 promotes cell proliferation and invasion in
lung cancer through directly interacting with and suppressing the
tumor suppressor miR-615-5p. Biosci Rep. 38:BSR201811502018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao W, Gu Y, Li Z, Cai H, Peng Q, Tu M,
Kondo Y, Shinjo K, Zhu Y, Zhang J, et al: miR-615-5p is
epigenetically inactivated and functions as a tumor suppressor in
pancreatic ductal adenocarcinoma. Oncogene. 34:1629–1640. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ji Y, Sun Q, Zhang J and Hu H: MiR-615
inhibits cell proliferation, migration and invasion by targeting
EGFR in human glioblastoma. Biochem Biophys Res Commun.
499:719–726. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang F, Zhao H, Du Z and Jiang H: miR-615
inhibits prostate cancer cell proliferation and invasion by
directly targeting cyclin D2. Oncol Res. 27:293–299. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu J, Jia Y, Jia L, Li T, Yang L and
Zhang G: MicroRNA 615-3p inhibits the tumor growth and metastasis
of NSCLC via inhibiting IGF2. Oncol Res. 27:269–279. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bai Y, Li J, Li J, Liu Y and Zhang B:
MiR-615 inhibited cell proliferation and cell cycle of human breast
cancer cells by suppressing of AKT2 expression. Int J Clin Exp Med.
8:3801–3808. 2015.PubMed/NCBI
|
|
33
|
Liu H, Liu N, Cheng Y, Jin W, Zhang P,
Wang X, Yang H, Xu X, Wang Z and Tu Y: Hexokinase 2 (HK2), the
tumor promoter in glioma, is downregulated by miR-218/Bmi1 pathway.
PLoS One. 12:e01893532017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Snezhkina AV, Krasnov GS, Zhikrivetskaya
SO, Karpova IY, Fedorova MS, Nyushko KM, Belyakov MM, Gnuchev NV,
Sidorov DV, Alekseev BY, et al: Overexpression of microRNAs miR-9,
−98, and −199 correlates with the downregulation of HK2 expression
in colorectal cancer. Mol Biol (Mosk). 52:220–230. 2018.(In
Russian). View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li W, Hao J, Zhang L, Cheng Z, Deng X and
Shu G: Astragalin reduces hexokinase 2 through increasing miR-125b
to inhibit the proliferation of hepatocellular carcinoma cells in
vitro and in vivo. J Agric Food Chem. 65:5961–5972. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gregersen LH, Jacobsen A, Frankel LB, Wen
J, Krogh A and Lund AH: MicroRNA-143 down-regulates hexokinase 2 in
colon cancer cells. BMC Cancer. 12:2322012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Song J, Wu X, Liu F, Li M, Sun Y, Wang Y,
Wang C, Zhu K, Jia X, Wang B and Ma X: Long non-coding RNA PVT1
promotes glycolysis and tumor progression by regulating miR-497/HK2
axis in osteosarcoma. Biochem Biophys Res Commun. 490:217–224.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou P, Chen WG and Li XW: MicroRNA-143
acts as a tumor suppressor by targeting hexokinase 2 in human
prostate cancer. Am J Cancer Res. 5:2056–2063. 2015.PubMed/NCBI
|
